Mankind Pharma has been assigned an Environmental, Social and Governance (ESG) rating of 71 by NSE Sustainability Ratings and Analytics Limited for FY26.

The rating was issued by NSE Sustainability, a SEBI-registered ESG Rating Provider, under Regulations 30 and 51 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. The company disclosed this development in a filing to stock exchanges on October 15, 2026.

Independent Assessment Methodology

A key distinction in this disclosure is the nature of the engagement. Mankind Pharma stated that it did not engage NSE Sustainability for this specific rating. Instead, the score was assigned independently by the agency using publicly available information.

This approach contrasts with solicited ratings where a company actively commissions an assessment. The independent nature suggests the rating reflects market-visible metrics and disclosures without direct input or pre-assessment dialogue with the company’s management team.

Disclosure Details

The company confirmed that the ESG rating details are also available on its official website. This transparency aligns with broader regulatory expectations for listed entities to maintain accessible records of their sustainability credentials.

What the Numbers Show

The assignment of a numerical score of 71 provides a quantifiable benchmark for investors assessing non-financial risks. While the source does not provide a peer comparison or historical trend, the fact that the rating was unsolicited indicates that Mankind Pharma’s existing public disclosures were sufficient to generate a standardized evaluation. For analysts, this serves as an external validation point derived solely from open-source data, potentially highlighting areas where voluntary disclosure practices have reached a level of maturity suitable for third-party scoring.

Mankind Pharma Limited disclosed that S.R. Batliboi & Co. LLP, the statutory auditors of its material wholly owned subsidiary Bharat Serums and Vaccines Limited (BSV), resigned from their role effective September 28, 2026. The resignation follows the initiation of voluntary liquidation proceedings for BSV under the Insolvency and Bankruptcy Code, 2016.

The move stems from a shareholder resolution passed on September 7, 2026, to liquidate BSV voluntarily. Under the Insolvency and Bankruptcy Board of India (Voluntary Liquidation Process) Regulations, 2017, a liquidator is prohibited from engaging any professional who served as an auditor for the company within five years preceding the liquidation commencement date. Consequently, S.R. Batliboi & Co. LLP tendered its resignation to comply with this regulatory requirement.

Regulatory Compliance and Timeline

The resignation was communicated via a letter dated September 28, 2026, addressed to the Board of Directors of BSV. The auditors confirmed that there were no other material reasons for their departure beyond the regulatory constraint imposed by the liquidation process. Mankind Pharma filed this disclosure with BSE and NSE pursuant to Regulations 30 and 51 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.

Key details regarding the auditor's tenure and the resignation are outlined below:

Audit Status and Next Steps

S.R. Batliboi & Co. LLP confirmed that they had completed the audit of BSV's financial statements for the year ended March 31, 2026, issuing the report on May 12, 2026. They had not commenced the audit for the fiscal year ending March 31, 2027. The firm stated it would file a statement in Form ADT-3 with the Registrar of Companies as required by the Companies Act, 2013.

The resignation highlights the procedural implications of corporate restructuring under Indian insolvency laws. When a company undergoes voluntary liquidation, the independence requirements for professionals assisting the liquidator extend to former auditors, necessitating a change in statutory audit firms even if the audit work was satisfactorily completed.